Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

Author:

Toja-Camba Francisco JoséORCID,Gesto-Antelo Nerea,Maroñas Olalla,Echarri Arrieta Eduardo,Zarra-Ferro Irene,González-Barcia MiguelORCID,Bandín-Vilar EnriqueORCID,Mangas Sanjuan VictorORCID,Facal FernandoORCID,Arrojo Romero Manuel,Carracedo AngelORCID,Mondelo-García CristinaORCID,Fernández-Ferreiro AnxoORCID

Abstract

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug monitoring (TDM) along with pharmacogenetic tests to improve safety and efficacy of antipsychotic pharmacotherapy. This comprehensive review aims to compile all the available pharmacokinetic and pharmacogenetic data regarding the three major LAI atypical antipsychotics: risperidone, paliperidone and aripiprazole. On the one hand, CYP2D6 metabolizer status influences the pharmacokinetics of LAI aripiprazole, but this relation remains a matter of debate for LAI risperidone and LAI paliperidone. On the other hand, developed population pharmacokinetic (popPK) models showed the influence of body weight or administration site on the pharmacokinetics of these LAI antipsychotics. The combination of pharmacogenetics and pharmacokinetics (including popPK models) leads to a personalized antipsychotic therapy. In this sense, the optimization of these treatments improves the benefit–risk balance and, consequently, patients’ quality of life.

Funder

Instituto de Salud Carlos III

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference131 articles.

1. A Systematic Review of the Prevalence of Schizophrenia

2. Informe Sobre la Salud en el Mundo 2001: Salud Mental: Nuevos Conocimientos, Nuevas Esperanzas,2001

3. Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology

4. Diagnostic and Statistical Manual of Mental Disorders,2013

5. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3